Neurofibromatosis treatment with Selumetinib (Koselugo)

Selumetinib (Koselugo) is the world's first drug officially sanctioned by the FDA for treating patients aged from two years with inoperable neurofibromas. Manufactured by the renowned pharmaceutical company AstraZeneca, Koselugo has achieved great success in clinical trials. The prescription of the drug significantly reduces pain syndrome, symptoms associated with motor disorders, airway patency, and overall quality of life. In addition, taking medicine slows down cell growth and division and reduces tumor volume. The drug is taken orally in the form of capsules. The dose and duration of taking this medication are selected individually and will vary for different patients. Koselugo therapy is continued as long as there is a clinical benefit. Your doctor must check your progress with regular visits. It will allow him to see if the medicine works properly and decide whether you should continue taking it. Blood and urine tests will be required to check for undesirable effects. Sometimes there may be side effects, such as loss of appetite, nausea, and dizziness, which usually do not require medical attention. They may disappear during treatment as your body adjusts to the medication. In addition, your doctor can tell you how to reduce some of these side effects.